Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 11:9:Doc01.
doi: 10.3205/hta000107. Print 2013.

Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests?

Lydia C B Fletcher  1 , Katie E Burke, Paul L Caine, Natasha L Rinne, Charlotte A Braniff, Hannah R Davis, Kathryn A Miles, Claire Packer
Affiliations

Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests?

Lydia C B Fletcher et al. GMS Health Technol Assess. .

Abstract

Background: Alzheimer's disease (AD) accounts for 60-80% of cases of dementia and causes significant morbidity in patients and carers, and expense for health and social services. There is a need for a validated, non-invasive and cheap test to diagnose early AD, as diagnosis may enable prompt treatment and service planning.

Aim: To identify emerging biomarker-based tests for the early diagnosis of AD which could be available for use in primary or generalist care in the near future.

Design: Horizon scanning review.

Methods: We searched online sources to identify emerging non-invasive, biomarker-based tests. Tests were included if they used blood, saliva or urine; and there was evidence of use in trials in patients with AD. For tests licensed for use in clinical or research settings we requested information from the developer on the intended place of use and plans for availability in Europe.

Results: We identified 6 biomarker-based tests of which 5 are available for research or clinical use. The closest to market were AclarusDX™ (ExonHit Therapeutics) a gene signature test, and INNO-BIA plasma Aβ forms assay (Innogenetics N.V.) which may be CE marked for clinical use in 2015. We found no evidence of clinical utility or cost.

Conclusion: Although biomarker-based tests are nearing clinical availability and may have a future role to help target AD-specific treatment and guide prognosis, they are not yet ready for trials of clinical utility in primary care.

Keywords: Alzheimer's disease; biomarker; dementia; diagnosis; emerging health technology; primary health care.

PubMed Disclaimer

Figures

Table 1
Table 1. Commercial tests – biomarker tests currently available for use in a clinical or research setting
Table 2
Table 2. Diagnostic biomarkers in earlier stages of clinical development
See this image and copyright information in PMC

References

    1. Luengo-Fernandez R, Leal J, Gray A. Dementia 2010. Alzheimer’s Research Trust: 2010.
    1. National Audit Office. Improving services and support for people with dementia, 2007. London: The Stationery Office; 2007.
    1. National Institute for Health and Clinical Excellence. Donepezil, galantimine, rivastigmine and memantine for the treatment of Alzheimer’s disease. 2011.
    1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet. 2006 Apr;367(9518):1262–1270. doi: 10.1016/S0140-6736(06)68542-5. Available from: http://dx.doi.org/10.1016/S0140-6736(06)68542-5. - DOI - PubMed
    1. Department of Health. Living well with dementia: a National Dementia Strategy. 2009.